Navigation Links
Bevacizumab offers no benefit for newly diagnosed glioblastoma, MD Anderson-led study finds
Date:2/19/2014

the drug as a frontline therapy -- even with virtually no data to support that decision. It was important from a patient care and regulatory standpoint that we conduct this trial."

The Phase III, international study (RTOG 0825) was a collaboration of three cooperative groups: RTOG, NCCTG and ECOG. The randomized, double-blind, placebo-controlled study registered 978 and enrolled 637 patients, respectively, all of whom were newly diagnosed with glioblastoma.

Participants underwent surgery to resect some or most of the tumor, received the standard of care of chemoradiation with temozolomide, and were randomized to receive either bevacizumab or placebo. The study was designed with two primary endpoints: PFS and overall survival OS.

Two distinguishing factors of the study design include: crossover to bevacizumab in the placebo arm at the time of progression, and longitudinal assessment of symptom burden, neurocognitive function and quality of life.

"With the crossover, we could determine the possible overall, or progression-free survival benefits that could distinguish the potential benefits of early versus later use of bevacizumab," Gilbert said. "Also, there may be some alternative advantages for delaying progression in the disease. In order to interpret that possible delay in progression, it was important to understand what the quality of the survival of that possible progression free survival interval."

A third distinction: the study was designed to look at the impact of pre-specified molecular markers -- a nine-gene signature expression and MGMT methylation -- to determine if a subgroup that specifically benefited from bevacizumab could be identified.

The researchers found no difference in OS between the bevacizumab and placebo arms, 15.7 and 16.1 months, respectively. PFS did not reach the pre-set level statistical significance -- although longer in those taking bevacizumab upfront (10.7 months), compared to i
'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Bevacizumab (Avastin) fails to improve survival for newly diagnosed glioblastoma patients
2. Phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer promising
3. Researchers detail possible resistance mechanisms of colorectal cancer to bevacizumab (Avastin)
4. Brain cancer survival improved following FDA approval of bevacizumab, Mayo study finds
5. Test helps target glioblastoma patients most likely to benefit from bevacizumab
6. Bevacizumab offers no benefit for newly diagnosed glioblastoma, M.D. Anderson-led study finds
7. Study finds glioblastoma patients treated with bevacizumab experience reduced cognitive function and quality of life
8. Time to tumor growth helps predict survival benefit of Bevacizumab for patients with metastatic colorectal cancer
9. Innovating for the Global South: New book offers practical insights
10. Fruit fly microRNA research at Rutgers-Camden offers clues to aging process
11. NIH study offers insight into why cancer incidence increases with age
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2015)... 25, 2015 World Patent Marketing, a ... the Hidee-Hose, an undergarment patent that allays women’s fears ... Women's Hosiery industry forecasts the market to reach $20.3 ... Creative Director of World Patent Marketing , "The ... ahead and is expected to maintain its lead. The ...
(Date:5/25/2015)... New York, New York (PRWEB) May 25, 2015 ... ( http://www.consumerinjurylawyers.com/depuy-pinnacle/lawsuit ) continue to move forward in ... District Court, Northern District of Texas. According to ... have asked the Court to modify the Case ... Disclose Health Information. Among other things, the Motion ...
(Date:5/25/2015)... Plains, NY (PRWEB) May 25, 2015 ... AP, principal of PBDW Architects in New York City, to ... is part of the hospital’s ongoing Legacy Lobby Lecture series, ... in White Plains. White is the great grandson of Stanford ... responsible for the design of Burke’s campus 100 years ago. ...
(Date:5/24/2015)... 24, 2015 For people who are ... Enterokinase Industry, 2009-2019 Market Research Report would be an ... exhaustive study on the present market scenario of this ... the growing Chinese market of this industry. The report ... status of the manufacturers in this industry. The report ...
(Date:5/24/2015)... 2015 ProPin is a set of ... X. Utilize ProPin to pin point locations on a map, ... , ProPin allows users to choose from 30 simplistic presets ... With on-screen controls, video editors can easily manipulate ProPin presets as ... mark with absolute ease. , Using ProPin is easy, simply drag ...
Breaking Medicine News(10 mins):Health News:For The Courtesy Of Women's Health And Looks - World Patent Marketing Presents A New Undergarment Patent 2Health News:For The Courtesy Of Women's Health And Looks - World Patent Marketing Presents A New Undergarment Patent 3Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 2Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 3Health News:Burke Rehabilitation Hospital Welcomes Architect Samuel White, Descendant of McKim, Mead and White, for Legacy Lobby Lecture 2Health News:Burke Rehabilitation Hospital Welcomes Architect Samuel White, Descendant of McKim, Mead and White, for Legacy Lobby Lecture 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 4Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2
... -- Alzheimer,s disease is gaining awareness as its ... with the disease. Previously unknown, misunderstood or hidden in ... family from Tioga, North Dakota -- are the subjects of ... for the disease, The Alzheimer,s Project shows there ...
... April 30 Rochester Medical Corporation (Nasdaq: ROCM ... March 31, 2009 compared to $9,215,000 for the second quarter ... of $361,000 or $.03 per diluted share for the current ... diluted share for the second quarter of last year.The approximate ...
... MillionCARLSBAD, Calif., April 30 Genoptix, Inc. (Nasdaq: ... reported revenues of $39.2 million for the first quarter ... changes in accounting estimates relating to prior periods. ... of $22.3 million for the comparable period in 2008, ...
... Mich. A new link between body fat and ... obesity,s health risk and could lead to new cancer ... food science and human nutrition researcher with the Michigan ... colon cancer, the third-leading killer of Americans, in part ...
... would like to announce the significant online growth of ... past few months Dynasplint(R) has been very busy building ... online. Their expansion includes two new web sites, a ... are intended to provide communication channels to their patients ...
... of children and grandchildren of DaVita teammates receive ... Inc. (NYSE: DVA ), a leading ... with chronic kidney disease (CKD), announced today that ... $1 million in funding for the educational pursuits ...
Cached Medicine News:Health News:The Alzheimer's Project HBO Documentary Puts Spotlight on Alzheimer's Disease; North Dakota Family Featured 2Health News:Rochester Medical Reports Second Quarter Results 2Health News:Rochester Medical Reports Second Quarter Results 3Health News:Rochester Medical Reports Second Quarter Results 4Health News:Rochester Medical Reports Second Quarter Results 5Health News:Rochester Medical Reports Second Quarter Results 6Health News:Rochester Medical Reports Second Quarter Results 7Health News:Rochester Medical Reports Second Quarter Results 8Health News:Rochester Medical Reports Second Quarter Results 9Health News:Rochester Medical Reports Second Quarter Results 10Health News:Rochester Medical Reports Second Quarter Results 11Health News:Rochester Medical Reports Second Quarter Results 12Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 2Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 3Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 4Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 5Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 6Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 7Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 8Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 9Health News:Cancer-obesity link discovery by MSU researchers could aid prevention efforts 2Health News:Dynasplint Systems, Inc. Launches Two New Web Sites Plus Social Media Tools 2Health News:DaVita Donates More Than $1 Million in Scholarship Funds for Teammates' Families 2
(Date:5/22/2015)... Calif. , May 22, 2015 /PRNewswire/ ... the Company has commenced termination of its ... brodalumab with AstraZeneca (LON:AZN, STO:AZN and NYSE: ... inhibitor, is in development for patients with ... spondyloarthritis.  The decision was based on events ...
(Date:5/22/2015)... CHAPEL HILL, N.C. , May 22, 2015 ... is critical to pharmaceutical brand recognition and success. ... Practices, LLC conducted a study to provide pharmaceutical ... level of investment (FTEs and budget) that are ... companies. Pharmaceutical and biotech marketing managers can utilize ...
(Date:5/22/2015)... May 22, 2015 Electrophysiologist Kevin Makati, ... traveled to Boston, MA ... 2015 Heart Rhythm Society conference. These scientific sessions ... on the ideas, people and technology that propel ... a hybrid, minimally invasive cardiac operation that combines ...
Breaking Medicine Technology:Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5Effective Marketing Services Group Critical for Pharmaceutical Brand Recognition 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3
... CAMBRIDGE, Mass., Oct. 25 GENFIT (Alternext: ALGFT; ISIN: ... discovery and development, focusing on the early diagnosis and ... that it has been selected by Windhover as one ... in the cardiovascular/metabolic category. This announcement is part of ...
... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... (FDA) has approved the real-time PCR COBAS® TaqMan® ... on COBAS® TaqMan® technology to support hepatitis C ... help clinicians to more confidently and effectively monitor ...
Cached Medicine Technology:GENFIT Selected by Windhover for the 2011 'Top Biopharma Projects To Watch' 2GENFIT Selected by Windhover for the 2011 'Top Biopharma Projects To Watch' 3Roche Receives FDA Approval for a Second-Generation Hepatitis C Viral Load Test 2Roche Receives FDA Approval for a Second-Generation Hepatitis C Viral Load Test 3
The Valleylab Surgistat II generator provides exceptional performance, reliability, and safety benefits in a compact, easy to use unit....
Lorgnette pinhole occluder...
Maddox rod and occluder...
Black multi-pinhole occluder...
Medicine Products: